Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OlympiaN
2023-503529-20-00Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of olaparib and durvalumab in breast cancer and Hereditary Breast Cancer (2 arms), sponsored by AstraZeneca. Primary endpoint: Pathological complete response (pCR). Started Oct 2022; status: completed.
02
Drugs
olaparibdurvalumab
03
Conditions
breast cancerHereditary Breast Cancer
Beyond the preview
Go deeper on 2023-503529-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503529-20-00.